Blueprint Medicines Corp Earnings

Blueprint Medicines Corp’s revenue jumped 103.41% since last year same period to $146.37Mn in the Q4 2024. On a quarterly growth basis, Blueprint Medicines Corp has generated 14.18% jump in its revenue since last 3-months.

Blueprint Medicines Corp’s net profit jumped 54.96% since last year same period to $-49.96Mn in the Q4 2024. On a quarterly growth basis, Blueprint Medicines Corp has generated 11.23% jump in its net profits since last 3-months.

Blueprint Medicines Corp’s net profit margin jumped 77.86% since last year same period to -34.13% in the Q4 2024. On a quarterly growth basis, Blueprint Medicines Corp has generated 22.26% jump in its net profit margins since last 3-months.

Blueprint Medicines Corp’s earning per share (EPS) estimates for the current quarter stand at -1.66 - a -132.46% fall from last quarter’s estimates.

Blueprint Medicines Corp’s earning per share (EPS) estimates for the current year stand at -1.66.

Blueprint Medicines Corp’s earning per share (EPS) jumped 56.59% since last year same period to -0.79 in the Q4 2024. This indicates that the Blueprint Medicines Corp has generated 56.59% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Blueprint Medicines Corp’s return on assets (ROA) stands at -0.12.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Blueprint Medicines Corp’s return on equity (ROE) stands at -0.31.